A Simple and Practical Scoring System for Radiosurgical Treatment in Patients with Brain Metastases

• Published in: Stereotactic and functional neurosurgery Vol. 98; no. 4; p. 278
• Main Authors: Lee, Sang Ryul, Roh, Tae Hoon, Jeong, Dong Hwan, You, Namkyu, Jang, Ae Hwa, Seo, Mi Ra, Choung, Jin Hee, Park, Bumhee, Kim, Se-Hyuk
• Format: Journal Article
• Language: English
• Published: Switzerland 01.08.2020
• Subjects: Gamma Knife radiosurgery; Prognosis; Metastasis; Survival; Radiosurgery
• ISSN: 1423-0372
• DOI: 10.1159/000507338

The study aimed to investigate the prognostic factors for patients with brain metastases undergoing radiosurgical treatment and to introduce a simple and practical scoring system for the prediction of survival time. We retrospectively analyzed data for 311 patients treated with Gamma Knife radiosurgery at a single institute. The mean age at time of treatment was 60 years (range 23-86 years), and the median Karnofsky performance status (KPS) score was 90 (range 60-100). Using a new prognostic index, the prognostic index for brain metastases (PIBM), the patients were categorized into 3 groups according to the primary tumor status and KPS score. We performed survival analysis and compared the prognostic ability of the PIBM with other published indices. During the median follow-up duration of 8.2 months (range 0.1-109 months), the median overall survival time was 9.1 months. Stable primary tumor status (hazard ratio [HR] 0.497, 95% confidence interval [CI] 0.321-0.769, p = 0.002) and KPS score ≥90 (HR 1.407, 95% CI 1.018-1.946, p = 0.039) significantly predicted longer overall survival. The PIBM showed the lowest Akaike information criterion value and the highest integrated area under the curve value compared with other prognostic indices. The PIBM may be a more accurate prognostic indicator than other published indices. Although this new and practical prognostic index requires further validation in larger cohort studies, we suggest that the PIBM could be useful to predict survival time and inform appropriate management of patients with brain metastases.